Matinas Biopharma Holdings, INC Form 4 insider transactions

Adam K Stern, a 10% owner of Matinas BioPharma Holdings, Inc., reported multiple transactions in common stock on October 16, 2025.

Sanitam Partners LLC reported changes in beneficial ownership of Matinas BioPharma Holdings, Inc. common stock on June 10, 2026.

GH Power and TKMS are evaluating clean energy technology integration for Canada's Future Patrol Submarine Project, potentially securing non-dilutive funding for GH Power.

Matinas BioPharma Holdings, Inc. announced a business combination with GH Power Inc., a clean energy and critical minerals company, aiming to list on the NYSE American.

Matinas BioPharma Holdings, Inc. has filed an SEC Form 425, providing disclosures related to its business and operations.

GH Power and Matinas BioPharma Holdings, Inc. have entered into a definitive business combination agreement to form a new Ontario-based public company, GH Power International.

Matinas BioPharma Holdings, Inc. announced a business combination with GH Power Inc. to form a clean energy company, alongside the sale of its LNC platform and MAT2203 to Azurity Pharmaceuticals.

Director Edward Neugeboren acquired stock options in Matinas BioPharma Holdings, Inc. subject to stockholder approval of the 2025 Equity Incentive Plan.

Director Robin L. Smith reports acquisition of stock options in Matinas BioPharma Holdings, Inc. subject to stockholder approval of the 2025 Equity Incentive Plan.

Director Evelyn D'An acquired stock options in Matinas BioPharma Holdings, Inc. subject to stockholder approval of the 2025 Equity Incentive Plan.

Matinas BioPharma Holdings CEO Jerome D. Jabbour was granted stock options for 70,100 shares, contingent on shareholder approval of the company's 2025 Equity Incentive Plan.

Director Keith Murphy receives stock options in Matinas BioPharma Holdings, Inc. subject to stockholder approval of the 2025 Equity Incentive Plan.

Sanitam Partners LLC reports acquisition of Series C Convertible Preferred Stock and warrants in Matinas BioPharma Holdings, Inc., impacting beneficial ownership.

Robert Eide, a director of Matinas BioPharma Holdings, reports changes in beneficial ownership including transactions involving Series C Convertible Preferred Stock and warrants.

Pembroke & Partners LLC reports acquiring Series C Convertible Preferred Stock and Warrants in Matinas BioPharma Holdings, Inc., increasing its beneficial ownership.